{
    "clinical_study": {
        "@rank": "94035", 
        "arm_group": [
            {
                "arm_group_label": "PVC Suppression then Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days."
            }, 
            {
                "arm_group_label": "Placebo then PVC Suppression", 
                "arm_group_type": "Placebo Comparator", 
                "description": "This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if reduction in premature ventricular contraction\n      (PVC) burden results in a decrease in blood pressure, sympathetic outflow, plasma\n      catecholamines and an improvement in baroreflex gain. Flecainide will be used for PVC\n      suppression in a randomized, double-blinded, crossover fashion."
        }, 
        "brief_title": "Premature Ventricular Contractions (PVCs) and Blood Pressure Control", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Ventricular Premature Complexes", 
            "Blood Pressure"
        ], 
        "condition_browse": {
            "mesh_term": "Ventricular Premature Complexes"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Frequent symptomatic premature ventricular contractions (PVCs) (>10% of total QRSs on\n             a 24-hour Holter)\n\n          -  Willingness to participate in research\n\n        Exclusion Criteria:\n\n          -  Age > 65 years old\n\n          -  Pacemaker implantation\n\n          -  Implantable cardioverter defibrillator implantation requiring pacing\n\n          -  Sick sinus syndrome\n\n          -  Atrio-ventricular (AV) block\n\n          -  Left ventricular dysfunction defined as left ventricular ejection fraction < 50%\n\n          -  History of myocardial infarction or coronary artery disease\n\n          -  Severe left ventricular hypertrophy (wall thickness > 1.5 cm by echocardiography\n             performed within 3 months from enrollment)\n\n          -  Severe liver dysfunction\n\n          -  Creatinine clearance of 35 mL/min/1.73 square meters or less\n\n          -  Pregnancy\n\n          -  Known hypersensitivity to the drug\n\n          -  QRS duration > 120 ms\n\n          -  Recent change in blood pressure medication within 30 days of enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01833455", 
            "org_study_id": "UW-PVC-2012-0510"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "PVC Suppression then Placebo", 
                    "Placebo then PVC Suppression"
                ], 
                "description": "Flecainide will be administered to result in a reduction in PVC burden.", 
                "intervention_name": "PVC Suppression using Flecainide", 
                "intervention_type": "Drug", 
                "other_name": "Tambocor"
            }, 
            {
                "arm_group_label": [
                    "PVC Suppression then Placebo", 
                    "Placebo then PVC Suppression"
                ], 
                "description": "Placebo (sugar pills) will be given to result in no alteration in PVC burden.", 
                "intervention_name": "No PVC Suppression using Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Flecainide"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 12, 2013", 
        "location": {
            "contact": {
                "email": "swasmund@medicine.wisc.edu", 
                "last_name": "Stephen L Wasmund, PhD", 
                "phone": "608-263-8005"
            }, 
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53792"
                }, 
                "name": "University of Wisconsin"
            }, 
            "investigator": {
                "last_name": "Mohamed Hamdan, MD, MBA", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effects of PVC Suppression on Blood Pressure Control in Patients With Frequent PVCs", 
        "other_outcome": {
            "measure": "Change in Baroreflex Gain", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 28 days"
        }, 
        "overall_contact": {
            "last_name": "Joy Amundson, MSN", 
            "phone": "608-262-0625"
        }, 
        "overall_official": {
            "affiliation": "University of Wisconsin, Madison", 
            "last_name": "Mohamed H Hamdan, MD, MBA", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in Blood Pressure", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01833455"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change in Muscle Sympathetic Nerve Activity", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 28 days"
        }, 
        "source": "University of Wisconsin, Madison", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Wisconsin, Madison", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}